(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 December 2006 (28.12.2006)

PCT

(10) International Publication Number
WO 2006/138217 A1

(51) International Patent Classification:
C07D 239/70 (2006.01) *C07D 471/10* (2006.01)
C07D 491/10 (2006.01) *C07D 487/10* (2006.01)
C07D 495/10 (2006.01)

(21) International Application Number:
PCT/US2006/022828

(22) International Filing Date: 12 June 2006 (12.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/690,538 14 June 2005 (14.06.2005) US

(71) Applicants *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US). **PHARMACOPEIA DRUG DISCOVERY, INC.** [US/US]; 3000 Eastpark Boulevard, Cranbury, New Jersey 08512 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ZHU, Zhaoning** [US/US]; 6 Cypress Court, Plainsboro, New Jersey 08536 (US). **MCKITTRICK, Brian** [US/US]; 14 Millbrook Road, New Vernon, New Jersey 07976 (US). **STAMFORD, Andrew, W.** [AU/US]; 27 Overlook Road, Chatham, New Jersey 07928 (US). **LE, Thuy, X.H.** [US/US]; 16 Black Gum Drive, Monmouth Junction, NJ 08852 (US). **GUO, Tao** [US/US]; 1606 Dahlia Circle, Dayton, NJ 08810 (US).

(74) Agent: **LEE, William, Y.**; Schering-Plough Corporation, 2000 Galloping Hill Road, Mail Stop K-6-1- 1990, Kenilworth, New Jersey 07033-0530 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASPARTYL PROTEASE INHIBITORS



(I)

(57) Abstract: Disclosed are compounds of the formula I here or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein U, W, A, R, R^1, R^2, R^{6a} and R^7, are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m_1 agonist or m_2 antagonist.

WO 2006/138217 A1